Pharmaceuticals company Kwality Pharmaceuticals announced Q1FY27 results Consolidated Financial Highlights: Total Revenue: For Q1FY27, the consolidated total revenue stood at Rs 16,297.49 lakh, representing an increase of 45.70% compared to Rs 11,185.47 lakh in Q1FY26 (YoY) and a growth of 3.04% from Rs 15,817.17 lakh in Q4FY26 (QoQ). Revenue from Operations: Net revenue from operations in Q1FY27 was Rs 16,235.22 lakh, up by 45.63% from Rs 11,147.90 lakh in Q1FY26 (YoY) and up by 3.33% from Rs 15,711.36 lakh in Q4FY26 (QoQ). Net Profit: The company reported a consolidated net profit for the period of Rs 2,562.23 lakh in Q1FY27, marking a significant growth of 114.96% compared to Rs 1,191.97 lakh in Q1FY26 (YoY) and an increase of 1.23% from Rs 2,531.05 lakh in Q4FY26 (QoQ). Earnings Per Share (EPS): Basic and diluted EPS for Q1FY27 stood at Rs 24.69, compared to Rs 11.49 in Q1FY26 and Rs 24.39 in Q4FY26. Total Comprehensive Income: The total comprehensive income for the period was Rs 2,571.23 lakh in Q1FY27, reflecting robust growth compared to Rs 1,207.08 lakh in Q1FY26. Standalone Financial Highlights: Total Revenue: Standalone total revenue for Q1FY27 was Rs 16,297.49 lakh, showing an increase of 45.70% from Rs 11,185.47 lakh in Q1FY26 (YoY) and a rise of 3.23% from Rs 15,788.04 lakh in Q4FY26 (QoQ). Revenue from Operations: Standalone net revenue from operations stood at Rs 16,235.22 lakh in Q1FY27, compared to Rs 11,147.90 lakh in Q1FY26 and Rs 15,682.24 lakh in Q4FY26. Net Profit: The standalone net profit reached Rs 2,562.68 lakh in Q1FY27, a growth of 114.77% against Rs 1,193.22 lakh in Q1FY26 (YoY) and a growth of 1.33% from Rs 2,529.11 lakh in Q4FY26 (QoQ). Earnings Per Share (EPS): Standalone basic and diluted EPS was Rs 24.70 for Q1FY27, compared to Rs 11.50 in Q1FY26 and Rs 24.37 in Q4FY26. Business Highlights: Guidance Update: Building on the momentum of a strong FY26, the management has raised FY27 guidance across key metrics: Revenue: Rs 700+ crore (+39%+ YoY). EBITDA: Rs 189-196+ crore (27-28%+ margin). PAT: Rs 109+ crore (~15.5%+ margin). R&D; and Clinical Programme: During the quarter, the company completed 13 Bioequivalence (BE) studies (7 from the General unit, 2 from Beta Lactam, and 4 from Oncology) as part of its 40-molecule BE programme. Filings have been made in 15+ countries. Product Registrations: The company secured 15+ new key product registrations across Malaysia, Algeria, Peru, and Mexico during the quarter. Biologics Front: Received approval to initiate pre-clinical batches for Pembrolizumab, adding a second biologics candidate. Erythropoietin has progressed to the clinical trial stage. Facility Update: Construction of the Hormone manufacturing facility is on schedule, with completion anticipated by November 2026. Global Presence: The company operates five manufacturing facilities and has a presence in over 70+ countries. Result PDF
Pharmaceuticals company Kwality Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights Revenue from operations (Net) for Q4FY26 stood at Rs 15,711.36 lakh, representing a growth of 27.28% QoQ compared to Rs 12,343.97 lakh in Q3FY26 and a YoY growth of 35.82% compared to Rs 11,567.64 lakh in Q4FY25. Total Revenue for Q4FY26 was Rs 15,817.17 lakh, an increase of 27.59% QoQ from Rs 12,396.74 lakh and 35.84% YoY from Rs 11,644.18 lakh. Profit After Tax (PAT) for Q4FY26 reached Rs 2,531.05 lakh, showing a significant growth of 58.19% QoQ from Rs 1,600.00 lakh in Q3FY26 and a growth of 74.80% YoY compared to Rs 1,447.99 lakh in Q4FY25. For the full year FY26, consolidated Revenue from operations (Net) reached Rs 50,308.34 lakh, marking a 35.90% increase from Rs 37,019.70 lakh in FY25. The Consolidated Profit After Tax for FY26 was Rs 6,734.60 lakh, representing a YoY growth of 69.20% compared to Rs 3,980.27 lakh in FY25. PAT margins for FY26 expanded to 13.4%, up from 10.8% in FY25. Basic Earnings Per Share (EPS) for FY26 stood at Rs 64.90, compared to Rs 38.36 in FY25. Standalone Financial Highlights Revenue from operations (Net) for Q4FY26 stood at Rs 15,682.24 lakh, recording a QoQ increase of 27.04% from Rs 12,344.45 lakh and a YoY increase of 35.57% from Rs 11,567.64 lakh. Total Revenue for Q4FY26 reached Rs 15,788.04 lakh, growing by 27.35% QoQ and 35.59% YoY. Profit After Tax (PAT) for Q4FY26 was Rs 2,529.11 lakh, reflecting a QoQ growth of 58.00% and a YoY growth of 74.44%. For the full year FY26, standalone Revenue from operations (Net) was Rs 50,305.89 lakh, up 35.89% from Rs 37,019.70 lakh in FY25. Standalone Profit After Tax for FY26 reached Rs 6,734.66 lakh, compared to Rs 3,988.97 lakh in FY25, registering a growth of 68.83% YoY. Basic Earnings Per Share (EPS) for FY26 was Rs 64.90, compared to Rs 38.44 in FY25. Business Highlights The company delivered a landmark financial performance in FY26, achieving its highest-ever quarterly and annual revenues and fulfilling the strategic revenue commitment outlined in FY23. EBITDA margins improved to 24% during FY26, an expansion of approximately 200 basis points from 22% in FY25, driven by an improved product mix and higher contributions from regulated markets. KPL clearing multiple international regulatory and customer audits, and its credit rating was upgraded by ICRA to BBB+ from B+. A large-scale Bioequivalence (BE) program was initiated, covering more than 40 Oral Solid Dosage (OSD) molecules to support global filings. Success was achieved in pre-clinical outcomes for Erythropoietin ("Kwalipoietin"), the company’s first biologic, which is on track for a planned FY27 launch. The company improved its overall cash conversion cycle from 208 days to 170 days and has recovered nearly 30% of delayed receivables from Middle Eastern partners. Management has targeted a doubling of revenues over the next three years, with an aspirational milestone of Rs 1,00,000 lakh by FY29. The company remains on track to achieve its FY27 guidance of Rs 65,000 lakh in revenues and Rs 10,000 lakh in PAT. Segment Performance: The company is primarily engaged in the business of Pharmaceuticals, which is its single reportable segment. Exceptional Items: The company recognised an exceptional expense of Rs 82.94 lakh in FY26 related to the incremental impact of new Labour Codes on past service cost for gratuity liability. Result PDF
Pharmaceuticals company Kwality Pharmaceuticals announced Q3FY26 results Revenue: Rs 123.4 crore against Rs 84.4 crore during Q3FY25, change 46%. EBITDA: Rs 30 crore against Rs 17.5 crore during Q3FY25, change 71%. PBT: Rs 22.3 crore against Rs 11.4 crore during Q3FY25, change 96%. PAT: Rs 16 crore against Rs 8.5 crore during Q3FY25, change 88%. Result PDF